NasdaqCM - Delayed Quote USD

Evoke Pharma, Inc. (EVOK)

0.4580 +0.0130 (+2.92%)
At close: April 26 at 4:00 PM EDT
0.4800 +0.02 (+4.80%)
After hours: April 26 at 4:40 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,180.6300
5,180.6300
2,508.6450
1,618.0760
23.0200
Cost of Revenue
201.8790
201.8790
370.3940
328.1180
86.7120
Gross Profit
4,978.7510
4,978.7510
2,138.2510
1,289.9580
-63.6920
Operating Expense
12,409.6420
12,409.6420
9,924.3880
9,441.6050
12,983.6570
Operating Income
-7,430.8910
-7,430.8910
-7,786.1370
-8,151.6470
-13,047.3490
Net Non Operating Interest Income Expense
-361.4040
-361.4040
-437.9930
-491.4350
-107.3220
Other Income Expense
--
--
--
105.1300
--
Pretax Income
-7,792.2950
-7,792.2950
-8,224.1300
-8,537.9520
-13,154.6710
Net Income Common Stockholders
-7,792.2950
-7,792.2950
-8,224.1300
-8,537.9520
-13,154.6710
Diluted NI Available to Com Stockholders
-7,792.2950
-7,792.2950
-8,224.1300
-8,537.9520
-13,154.6710
Basic EPS
-2.33
-2.33
-2.62
-3.18
-6.24
Diluted EPS
-2.33
-2.33
-2.62
-3.18
-6.24
Basic Average Shares
3,343.0700
3,343.0700
3,143.6260
2,682.1450
2,124.3380
Diluted Average Shares
3,343.0700
3,343.0700
3,143.6260
2,682.1450
2,124.3380
Total Operating Income as Reported
-7,430.8910
-7,430.8910
-7,786.1370
-8,151.6470
-13,047.3490
Total Expenses
12,611.5210
12,611.5210
10,294.7820
9,769.7230
13,070.3690
Net Income from Continuing & Discontinued Operation
-7,792.2950
-7,792.2950
-8,224.1300
-8,537.9520
-13,154.6710
Normalized Income
-7,792.2950
-7,792.2950
-8,224.1300
-8,643.0820
-13,154.6710
Interest Income
138.5960
138.5960
62.0070
8.6150
5.6720
Interest Expense
500.0000
500.0000
500.0000
500.0500
112.9940
Net Interest Income
-361.4040
-361.4040
-437.9930
-491.4350
-107.3220
EBIT
-7,292.2950
-7,292.2950
-7,724.1300
-8,037.9020
-13,041.6770
EBITDA
-7,292.2950
-7,292.2950
-7,724.1300
-8,037.9020
-13,041.6770
Reconciled Cost of Revenue
201.8790
201.8790
370.3940
328.1180
86.7120
Net Income from Continuing Operation Net Minority Interest
-7,792.2950
-7,792.2950
-8,224.1300
-8,537.9520
-13,154.6710
Total Unusual Items Excluding Goodwill
--
--
--
105.1300
--
Total Unusual Items
--
--
--
105.1300
--
Normalized EBITDA
-7,292.2950
-7,292.2950
-7,724.1300
-8,143.0320
-13,041.6770
12/31/2020 - 9/25/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

YCBD cbdMD, Inc.
0.8711
-3.21%
 
CT9.F Cardiol Therapeutics Inc.
1.6320
+0.62%
 
PCLOF PharmaCielo Ltd.
0.1153
+1.23%
 
KAYS Kaya Holdings, Inc.
0.0430
+10.26%
 
VEXT.CN Vext Science, Inc.
0.2400
+2.13%
 
LVVV LiveWire Ergogenics, Inc.
0.0018
+12.50%
 
AAWH-U.CN Ascend Wellness Holdings, Inc.
1.2800
+3.23%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.65
+3.31%
 
CNPOF RIV Capital Inc.
0.0803
+0.38%
 
MYCOF Mydecine Innovations Group Inc.
0.0221
+72.58%